In a study of patients with ankylosing spondylitis (AS), the rate of anterior uveitis was reduced upon treatment with adalimumab (n = 406) or infliximab (n = 605) compared with pretreatment rates. The opposite was seen in patients receiving etanercept treatment (n = 354). Treatment with etanercept was associated with an increased risk of anterior uveitis compared with adalimumab (HR 3.86, 95% CI 1.85–8.06) or influximab (HR 1.99, 95% CI 1.23–3.22), whereas no significant differences were observed between adalimumab and infliximab treatment.